Literature DB >> 7909624

Nephrotoxicity mechanism of cis-platinum (II) diamine dichloride in mice.

M Ban1, D Hettich, N Huguet.   

Abstract

Male Swiss OF1 mice were injected subcutaneously with 20 mg/kg of cis-platinum (II) diamine dichloride (cis-platin). Examination of cryostat kidney sections stained for alkaline phosphatase (APP) revealed damage to about 10, 20, 40 and 50% of the proximal tubules after 7, 24, 48 and 72 h, respectively. Pretreatment with the glutathione synthesis inhibitor, buthionine sulfoximine (BSO), (i.p. 3 mmol/kg) potentiated the tubule damage of cis-platin. In contrast, pretreatment with organic anion transport inhibitor probenecid (i.p. 3 x 0.75 mmol/kg) reduced the number of damaged tubules by approximately 80% at 72 h after cis-platin injection. Pretreatment with the gamma-glutamyltranspeptidase (gamma-GT) inactivator acivicin (AT-125, 50 mg/kg p.o., plus 50 mg/kg i.p.) failed to prevent cis-platin induced renal toxicity. Pretreatment with the beta-lyase inactivator aminooxyacetic acid (AOAA, 2 x 100 mg/kg p.o.) and with the renal cysteine conjugate S-oxidase inhibitor methimazole (40 mg/kg i.p.) reduced the number of damaged tubules by approximately 40% and 75%, respectively in mice treated with cis-platin. The results suggest that the platinum-sulfhydryl group complexes formed are taken up by the kidney cells through an organic anion transport mechanism which is probenecid-sensitive. In the cells these complexes are stable for several hours, depending on the intracellular glutathione (GSH) level, and gradually undergo transformation to reactive metabolite(s) by renal intracellular beta-lyase and S-oxidase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909624     DOI: 10.1016/0378-4274(94)90176-7

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  9 in total

Review 1.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system.

Authors:  K Husain; C Morris; C Whitworth; G L Trammell; L P Rybak; S M Somani
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

Review 3.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

4.  Azadirachta indica attenuates cisplatin-induced neurotoxicity in rats.

Authors:  Ahmed Esmat Abdel Moneim
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

5.  Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.

Authors:  S Hu; A F Leblanc; A A Gibson; K W Hong; J Y Kim; L J Janke; L Li; A Vasilyeva; D B Finkelstein; J A Sprowl; D H Sweet; E Schlatter; G Ciarimboli; Jhm Schellens; S D Baker; N Pabla; A Sparreboom
Journal:  Clin Transl Sci       Date:  2017-07-08       Impact factor: 4.689

6.  Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.

Authors:  Y Mizumura; Y Matsumura; T Hamaguchi; N Nishiyama; K Kataoka; T Kawaguchi; W J Hrushesky; F Moriyasu; T Kakizoe
Journal:  Jpn J Cancer Res       Date:  2001-03

7.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

8.  Protective Role of Aerobic Exercise Against Cisplatin-Induced Nephrotoxicity in Rats.

Authors:  Farzaneh Zeynali; Mehdi Nematbakhsh; Hossain Mojtahedi; Aliasghar Poorshahnazari; Ardeshir Talebi; Zahra Pezeshki; Safoora Mazaheri; Fatemeh Moslemi
Journal:  Asian J Sports Med       Date:  2015-09-28

9.  Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies.

Authors:  Midori Tanaka; Hidehito Horinouchi; Yasushi Goto; Shintaro Kanda; Yutaka Fujiwara; Hiroshi Nokihara; Noboru Yamamoto; Yuichiro Ohe
Journal:  ESMO Open       Date:  2018-05-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.